Peking University Cancer Hospital & Institute: Breast Neoplasms trials

The registry lists 25 Breast Neoplasms studies with Peking University Cancer Hospital & Institute as lead sponsor. 13 are open to participants now and 1 have results posted.

Phase 1 1Phase 2 7Phase 4 2No phase 16(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide ProbesRecruitingNCT07848243Phase 2
• SLNB Combined With WLNB for Axillary De-escalation in Breast Cancer Patients With Abnormal Axillary NodesNot yet recruitingNCT07791771
• Abemaciclib Dose Escalation in Early High-Risk Breast Cancer Adjuvant TherapyNot yet recruitingNCT07599137Phase 4
• 5T4 Targeting Nanobody Probe for PET Imaging in Solid TumorsNot yet recruitingNCT07589101Not applicable
• Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular ImagingNot yet recruitingNCT07527806Phase 2
• SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized StudyNot yet recruitingNCT07417241Phase 2
• Hand and Foot Bath for Taxane-Induced Peripheral NeurotoxicityNot yet recruitingNCT07344974Phase 4
• Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World StudyRecruitingNCT07251868
• A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain MetastasesNot yet recruitingNCT07177950Phase 1/2
• Comparative Research on the Accuracy of Margin Interpretation in Breast-Conserving Surgery for Breast Cancer: Cell Microscopic Imaging and Standard Frozen PathologyNot yet recruitingNCT07029646Not applicable
• Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker ExplorationRecruitingNCT06991790
• Al18F-HER2-BCH PET in Breast Patients Treated With ADC TherapyRecruitingNCT06909604Not applicable
• Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular ImagingRecruitingNCT06715020Not applicable
• Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)CompletedNCT02878057Phase 2Results posted
• Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast CancerActive, not recruitingNCT07018427
• Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast CancerStatus unknownNCT05577442Phase 2
• Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With TrastuzumabStatus unknownNCT05188495
• Nab-paclitaxel Dose Schedual for HER-2 Negative Advanced Breast CancerStatus unknownNCT04192331Phase 2
• Prognosis and Targeted Therapy Related Molecular Screening Program for Patients of Breast Cancer in ChinaStatus unknownNCT03792529
• Study of Chemotherapy With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer PatientsCompletedNCT01395056
• Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural EffusionCompletedNCT01256801
• Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer PatientsCompletedNCT01232062
• Study the Role of Stem Cell in Curing Drug Induced Liver Injury in Metastatic Breast Cancer (MBC)CompletedNCT01231022
• Genetic Polymorphisms Predict Chemotherapeutic Outcomes in Patients With Metastatic Breast CancerCompletedNCT01199393
• Gene Expression Profiling of Metastatic Breast Cancer Predict the Therapeutic Response to ChemotherapyCompletedNCT01198301